List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/26146/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Age Factor in Postbariatric Body Contouring Surgery Outcome. Plastic and Reconstructive Surgery, 2022, 149, 417e-423e.	1.4	3
2	Rectracted: Anti-ribosomal-phosphoprotein autoantibodies penetrate to neuronal cells via neuronal growth associated protein, affecting neuronal cells <i>in vitro</i> . Rheumatology, 2021, 60, e456-e466.	1.9	1
3	The pathogenic role of circulating Hashimoto's Thyroiditisâ€derived TPOâ€positive IgG on fetal loss in naÃ⁻ve mice. American Journal of Reproductive Immunology, 2021, 85, e13331.	1.2	4
4	Infusion of anti-DFS70 antibodies prolonged survival of lupus-prone mice. Lupus, 2021, 30, 320-324.	1.6	6
5	Autoimmune dysautonomia in women with silicone breast implants. Journal of Autoimmunity, 2021, 120, 102631.	6.5	24
6	Letter to the Editor. Parasitology International, 2021, 83, 102350.	1.3	0
7	Immunomodulation of Murine Chronic DSS-Induced Colitis by Tuftsin–Phosphorylcholine. Journal of Clinical Medicine, 2020, 9, 65.	2.4	10
8	Tuftsin-phosphorylcholine attenuate experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2019, 337, 577070.	2.3	15
9	Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor. Frontiers in Immunology, 2019, 10, 650.	4.8	3
10	Helminthes and Autoimmunity, a Love Story. , 2019, , 639-642.		0
11	Helminth-Based Product and the Microbiome of Mice with Lupus. MSystems, 2019, 4, .	3.8	22
12	The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. Journal of Autoimmunity, 2019, 98, 113-121.	6.5	7
13	Helminth-Related Tuftsin-Phosphorylcholine Compound and its Interplay with Autoimmune Diseases. Israel Medical Association Journal, 2019, 21, 158-162.	0.1	1
14	The Second Greek-Israeli Symposium on Autoimmunity and Rheumatology: Success Through Synergy. Israel Medical Association Journal, 2019, 21, 292-297.	0.1	0
15	Are Anti-DFS70 Autoantibodies Protective?. Israel Medical Association Journal, 2019, 21, 509-511.	0.1	14
16	Tuftsin phosphorylcholine—a novel compound harnessing helminths to fight autoimmunity. Immunologic Research, 2018, 66, 637-641.	2.9	10
17	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews, 2018, 17, 1153-1168.	5.8	62
18	Helminths-based bi-functional molecule, tuftsin-phosphorylcholine (TPC), ameliorates an established murine arthritis. PLoS ONE, 2018, 13, e0200615.	2.5	17

#	Article	IF	CITATIONS
19	Prevalence of anti-DFS70 antibodies in patients with and without systemic autoimmune rheumatic diseases. Clinical and Experimental Rheumatology, 2018, 36, 121-126.	0.8	31
20	The effect of Intravenous Immunoglobulin (IVIG) on extit{ex vivo} activation of human leukocytes. Human Antibodies, 2017, 24, 39-44.	1.5	15
21	ls autoimmunology a discipline of its own? A big data-based bibliometric and scientometric analyses. Autoimmunity, 2017, 50, 269-274.	2.6	11
22	Novelties in the field of autoimmunity – 1st Saint Petersburg congress of autoimmunity, the bridge between east and west. Autoimmunity Reviews, 2017, 16, 1175-1184.	5.8	17
23	Major Histocompatibility Complex Class II Alleles Influence Induction of Pathogenic Antiphospholipid Antibodies in a Mouse Model of Thrombosis. Arthritis and Rheumatology, 2017, 69, 2052-2061.	5.6	9
24	Phospholipid supplementation can attenuate vaccine-induced depressive-like behavior in mice. Immunologic Research, 2017, 65, 99-105.	2.9	16
25	Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil. Immunologic Research, 2017, 65, 136-149.	2.9	40
26	Adjuvants- and vaccines-induced autoimmunity: animal models. Immunologic Research, 2017, 65, 55-65.	2.9	42
27	Tuftsin-Phosphorylcholine Maintains Normal Gut Microbiota in Collagen Induced Arthritic Mice. Frontiers in Microbiology, 2017, 8, 1222.	3.5	25
28	Some like it hot: The emerging role of spicy food (capsaicin) in autoimmune diseases. Autoimmunity Reviews, 2016, 15, 451-456.	5.8	28
29	Successful modulation of murine lupus nephritis with tuftsin-phosphorylcholine. Journal of Autoimmunity, 2015, 59, 1-7.	6.5	36
30	Unraveling the Hygiene Hypothesis of helminthes and autoimmunity: origins, pathophysiology, and clinical applications. BMC Medicine, 2015, 13, 81.	5.5	129
31	Phosphorylcholine-tuftsin compound prevents development of dextransulfate-sodium-salt induced murine colitis: Implications for the treatment of human inflammatory bowel disease. Journal of Autoimmunity, 2015, 56, 111-117.	6.5	32
32	Passive transfer of affinity-purified anti-heart autoantibodies (AHA) from sera of patients with myocarditis induces experimental myocarditis in mice. International Journal of Cardiology, 2015, 179, 166-177.	1.7	40
33	The mechanisms behind helminth's immunomodulation in autoimmunity. Autoimmunity Reviews, 2015, 14, 98-104.	5.8	47
34	Anti-ribosomal-P antibodies accelerate lupus glomerulonephritis and induce lupus nephritis in naÃ⁻ve mice. Journal of Autoimmunity, 2014, 54, 118-126.	6.5	16
35	Antibody-specific behavioral effects: Intracerebroventricular injection of antiphospholipid antibodies induces hyperactive behavior while anti-ribosomal-P antibodies induces depression and smell deficits in mice. Journal of Neuroimmunology, 2014, 272, 10-15.	2.3	53
36	IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nature Reviews Immunology, 2014, 14, 349-349.	22.7	68

#	Article	IF	CITATIONS
37	Tolerogenic dendritic cells specific for β2-glycoprotein-l Domain-I, attenuate experimental antiphospholipid syndrome. Journal of Autoimmunity, 2014, 54, 72-80.	6.5	25
38	Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model. Journal of Autoimmunity, 2014, 54, 21-32.	6.5	64
39	Hypercoagulability in celiac disease — An update. Autoimmunity Reviews, 2014, 13, 1138-1141.	5.8	33
40	Anti-GalNAcβ: A novel anti-glycan autoantibody associated with pregnancy loss in women with antiphospholipid syndrome and in a mouse experimental model. Journal of Autoimmunity, 2012, 39, 420-427.	6.5	8
41	β2-Glycoprotein-I based peptide regulate endothelial-cells tissue-factor expression via negative regulation of pCSK3β expression and reduces experimental-antiphospholipid-syndrome. Journal of Autoimmunity, 2011, 37, 8-17.	6.5	23
42	Sialic acid–IVIg targeting CD22. Blood, 2010, 116, 1630-1632.	1.4	11
43	Antiphospholipid Antibody-Mediated Reproductive Failure in Antiphospholipid Syndrome. Clinical Reviews in Allergy and Immunology, 2010, 38, 141-147.	6.5	30
44	The Pathophysiology of the Catastrophic Antiphospholipid Syndrome: Compelling Evidence. Clinical Reviews in Allergy and Immunology, 2010, 39, 207-207.	6.5	0
45	Histidine-Rich Glycoprotein Modulation of Immune/Autoimmune, Vascular, and Coagulation Systems. Clinical Reviews in Allergy and Immunology, 2008, 34, 307-312.	6.5	58
46	The story of the 16/6 idiotype and systemic lupus erythematosus. Israel Medical Association Journal, 2008, 10, 37-9.	0.1	15
47	B cell targeted therapy in autoimmunity. Journal of Autoimmunity, 2007, 28, 62-68.	6.5	62
48	The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. International Immunology, 2007, 19, 857-865.	4.0	69
49	Molecular mimicry and auto-immunity. Clinical Reviews in Allergy and Immunology, 2007, 32, 111-118.	6.5	112
50	Molecular mimicry and auto-immunity. Clinical Reviews in Allergy and Immunology, 2007, 32, 111-118.	6.5	17
51	Toward Molecular Targeting With Specific Intravenous Immunoglobulin Preparation. Clinical Reviews in Allergy and Immunology, 2005, 29, 213-218.	6.5	19
52	Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations. Clinical Immunology, 2004, 112, 190-199.	3.2	71
53	Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. International Immunology, 2002, 14, 121-129.	4.0	118
54	Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. International Immunology, 2002, 14, 1303-1311.	4.0	85

#	Article	IF	CITATIONS
55	The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis and Rheumatism, 2002, 46, 1689-1690.	6.7	67
56	Induction of oral tolerance in experimental antiphospholipid syndrome by feeding with polyclonal immunoglobulins. European Journal of Immunology, 2002, 32, 3414-3424.	2.9	8
57	Bacterial induction of autoantibodies to \hat{l}^22 -glycoprotein-l accounts for the infectious etiology of antiphospholipid syndrome. Journal of Clinical Investigation, 2002, 109, 797-804.	8.2	156
58	Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: The pathogenic and diagnostic implications. Arthritis and Rheumatism, 2001, 44, 1484-1494.	6.7	114
59	Monoclonal anti-endothelial cell antibodies from a patient with Takayasu arteritis activate endothelial cells from large vessels. Arthritis and Rheumatism, 1999, 42, 1421-1432.	6.7	59
60	Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice. Journal of Clinical Immunology, 1998, 18, 52-60.	3.8	39
61	Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony-stimulating factor expression. Arthritis and Rheumatism, 1998, 41, 224-232.	6.7	50
62	Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukinâ€3 and granulocyteâ€macrophage colonyâ€stimulating factor expression. Arthritis and Rheumatism, 1998, 41, 224-232.	6.7	2
63	Characterization of biologically active antineutrophil cytoplasmic antibodies induced in mice:pathogenetic role in experimental vasculitis. Arthritis and Rheumatism, 1995, 38, 1375-1381.	6.7	60
64	Antiphospholipid Syndrome: From the Laboratory Bench to the Patients' Bedside. Lupus, 1995, 4, S33-S36.	1.6	5
65	The Effect of Aspirin on Recurrent Fetal Loss in Experimental Antiphospholipid Syndrome. American Journal of Reproductive Immunology, 1993, 29, 155-161.	1.2	62
66	Systemic Vasculitis Autoantibodies Targeting Endothelial Cells. , 0, , 1411-1418.		0
67	Molecular Mimicry: Lessons from Experimental Models of Systemic Lupus Erythematosus and Antiphospholipid Syndrome. , 0, , 223-233.		1